#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16616	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2628	778.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1703	1703	C	1048	C,G	1047,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28392	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	847.5	0	.	n	.	0	T695C	SNP	695	695	T	1363	1363	C	1046	C,T,A	1042,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28392	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	847.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	2005	2005	A	1221	A,G	1219,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28392	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	847.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2639	2639	C	1008	C,T,G,A	1003,2,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28392	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	847.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2713	2713	A	929	A,C,T,G	924,1,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28392	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	847.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3265	3265	C	949	C,A,T	946,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2252	folP	852	852	100.0	folP.l6.c30.ctg.1	2044	137.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1192	1194	AGC	209;209;210	A,G;G;C	208,1;209;210	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5220	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3989	163.1	1	SNP	p	S91F	0	.	.	271	273	TCC	922	924	TCC	207;209;208	T;C;C	207;209;208	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5220	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3989	163.1	1	SNP	p	D95N	0	.	.	283	285	GAC	934	936	GAC	213;215;214	G;A,T;C	213;214,1;214	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5220	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3989	163.1	1	SNP	p	D95G	0	.	.	283	285	GAC	934	936	GAC	213;215;214	G;A,T;C	213;214,1;214	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_MC58_v2_01735	mtrR.Neisseria_meningitidis_MC58_v2_01735	1	1	27	2120	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1831	144.4	1	SNP	p	G45D	0	.	.	133	135	GGC	712	714	GGC	241;238;240	G;G;C	241;238;240	mtrR.Neisseria_meningitidis_MC58_v2_01735:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	368	mtrR_promoter	250	250	97.2	mtrR_promoter.l15.c30.ctg.1	892	44.9	0	.	n	.	0	A125G	SNP	125	125	A	370	370	G	95	G,A,C	93,1,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	368	mtrR_promoter	250	250	97.2	mtrR_promoter.l15.c30.ctg.1	892	44.9	0	.	n	.	0	C147T	SNP	147	147	C	392	392	T	106	T,C	105,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	368	mtrR_promoter	250	250	97.2	mtrR_promoter.l15.c30.ctg.1	892	44.9	0	.	n	.	0	T159C	SNP	159	159	T	404	404	C	132	C,T	131,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	368	mtrR_promoter	250	250	97.2	mtrR_promoter.l15.c30.ctg.1	892	44.9	0	.	n	.	0	C189T	SNP	189	189	C	434	434	T	135	T,C	134,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	368	mtrR_promoter	250	250	97.2	mtrR_promoter.l15.c30.ctg.1	892	44.9	0	.	n	.	0	A192T	SNP	192	192	A	437	437	T	129	T,A	128,1	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	368	mtrR_promoter	250	250	97.2	mtrR_promoter.l15.c30.ctg.1	892	44.9	0	.	n	.	0	A195C	SNP	195	195	A	440	440	C	123	C	123	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	368	mtrR_promoter	250	250	97.2	mtrR_promoter.l15.c30.ctg.1	892	44.9	0	.	n	.	0	G221A	SNP	221	221	G	466	466	A	83	A,G	82,1	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5666	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	209.6	1	SNP	p	D86N	0	.	.	256	258	GAC	847	849	GAC	242;240;241	G;A,T,G;C	242;238,1,1;240	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5666	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	209.6	1	SNP	p	S87W	0	.	.	259	261	AGT	850	852	AGT	244;245;247	A;G;T	243;245;247	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5666	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	209.6	1	SNP	p	S87I	0	.	.	259	261	AGT	850	852	AGT	244;245;247	A;G;T	243;245;247	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5666	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	209.6	1	SNP	p	S87R	0	.	.	259	261	AGT	850	852	AGT	244;245;247	A;G;T	243;245;247	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5666	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3362	209.6	1	SNP	p	S88P	0	.	.	262	264	TCC	853	855	TCC	250;249;250	T,C;C,T,G;C	249,1;247,1,1;250	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4476	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3201	174.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1819	1821	GGC	254;252;256	G,T,A;G;C,G	252,1,1;252;255,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1517	1519	GCA	259;259;256	G;C,A;A,C	259;258,1;255,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1520	1522	ATC	250;251;250	A;T;C	250;251;250	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1532	1534	GTG	245;247;243	G;T;G,T,C	244;246;240,1,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1532	1534	GTG	245;247;243	G;T;G,T,C	244;246;240,1,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2036	2038	ACC	233;232;231	A,C;C;C	232,1;232;231	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2090	2092	GCG	247;250;249	G;C,T;G,T	247;249,1;248,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2090	2092	GCG	247;250;249	G;C,T;G,T	247;249,1;248,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2213	2215	GGC	257;255;253	G,T;G;C	256,1;255;253	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2222	2224	GGC	253;253;254	G;G;C	253;253;254	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2835	189.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2240	2242	CCG	245;245;245	C;C;G	245;245;245	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6116	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3665	207.7	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1894	1896	CTG	219;219;216	C;T;G,C	219;219;215,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2632	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2439	134.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	862	862	C	172	C	172	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3406	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2033	208.0	1	SNP	p	G120K	0	.	.	358	360	GGC	830	832	GGC	289;289;287	G,A;G;C	288,1;289;287	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3406	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2033	208.0	1	SNP	p	A121D	1	.	.	361	363	GAC	833	835	GAC	289;291;291	G;A,G,C;C,T,A	289;289,1,1;289,1,1	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3406	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2033	208.0	1	SNP	p	D121N	0	.	.	361	363	GAC	833	835	GAC	289;291;291	G;A,G,C;C,T,A	289;289,1,1;289,1,1	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11476	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5269	271.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2213	2215	AAT	276;274;278	A,C;A,T;T,C	275,1;273,1;277,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1624	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1503	134.4	1	SNP	p	V57M	1	.	.	169	171	ATG	712	714	ATG	278;277;279	A;T;G	278;277;279	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
